Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
105Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.38M | $-21.64M | $-0.25 |
| 2024 | $26.92M | $-24.05M | $-0.30 |
| 2023 | $26.77M | $-20.71M | $-0.27 |
| 2022 | $28.15M | $-18.29M | $-0.26 |
| 2021 | $35.02M | $-10.72M | $-0.16 |
Social Signal Score
Earnings
Tue, Nov 10(in 3 months)
Consensus estimate $-0.04 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.05 vs $-0.05beat
- Tue, May 12$-0.03 vs $-0.04beat
- Mon, Mar 9$-0.06 vs $-0.06beat
- Tue, Nov 11$-0.03 vs $-0.06beat
- Thu, Aug 7$-0.05 vs $-0.07beat
- Mon, May 12$-0.07 vs $-0.07beat
Estimates and results for STXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
STXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (4)
- Newsseekingalpha.com·3d ago·Positive
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·3d ago·Positive
Stereotaxis Q2 Earnings Call Highlights Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
View source ↗ - Newszacks.com·3d ago·Negative
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.
View source ↗